Switching from Tirzepatide to Semaglutide: Zepbound/Mounjaro to Wegovy/Ozempic

Written by the GLP-1 Coach editorial team. Last updated October 1, 2026.

Most switching content runs in one direction: semaglutide to tirzepatide, chasing the bigger average weight loss. The reverse switch — Zepbound or Mounjaro to Wegovy or Ozempic — is common too, but it usually happens for different reasons, and it is not simply the semaglutide-to-tirzepatide switch played backwards.

It also sits in a real evidence gap. There is no official dose conversion between the two drugs, no label instruction for this specific switch, and no study that followed people through it. This article lays out what is actually documented, and says plainly where the documentation stops.

Why do people switch from tirzepatide to semaglutide?

Rarely because semaglutide is expected to work better. The usual reasons are practical:

• Insurance and formulary changes. This is the best-documented driver. CVS Caremark removed Zepbound from its standard commercial formulary on July 1, 2025, leaving Wegovy as the preferred option. An analysis of dispensing records from Truveta found that switching away from weight-management tirzepatide jumped from a monthly average of 0.6% (January–April 2025) to 9.6% in July 2025, and that 82.8% of those who switched moved to semaglutide. That analysis is preliminary and not peer reviewed, and it tracked prescriptions only — not what happened to anyone's weight or side effects afterward.
• That same decision has since been reversed. On May 28, 2026, CVS Caremark announced Zepbound would return as an additional preferred option effective October 1, 2026, while noting that plan sponsors using its template formularies "retain discretion to customize coverage." If a formulary change is your reason for switching, confirm your own plan's current status first — our guide to losing GLP-1 coverage covers who to call and what to ask.
• Side effects on tirzepatide. Some people don't tolerate tirzepatide and their prescriber suggests trying a different molecule. Worth knowing before you expect relief: in the head-to-head SURMOUNT-5 trial, fewer people stopped tirzepatide for gastrointestinal reasons (2.7%) than stopped semaglutide (5.6%). The trial's investigators also reported more injection-site reactions with tirzepatide than with semaglutide. Trial averages don't settle what an individual will experience, but they don't support the assumption that semaglutide is the easier drug on the stomach.
• A labeled use that only one drug has. Wegovy's label includes reducing the risk of major adverse cardiovascular events in certain adults, and treatment of noncirrhotic MASH (a form of fatty liver disease) with moderate to advanced liver fibrosis in adults. Zepbound's label includes moderate-to-severe obstructive sleep apnea in adults with obesity. A prescriber may prefer the drug whose label matches the condition they are treating.
• Preferring a pill. Wegovy is available as a once-daily tablet. Zepbound is injection only.
• Supply. This was a major reason during the 2022–2024 shortages. The FDA has since declared both shortages resolved (background in our compounded GLP-1 explainer), so it is a less common driver now.

A 2026 clinical review in The Pharmaceutical Journal lists the same cluster of reasons for switching between these two drugs: "adverse effects, patient preference, cost pressures or formulary decisions."

Is there a dose conversion between tirzepatide and semaglutide?

No official one exists. This is the central fact of the switch, so it is worth being exact about what that means:

• The FDA labels contain no conversion. Neither the Wegovy nor the Zepbound prescribing information includes a table, ratio, or instruction for moving a patient from one to the other.
• No switching trial has been run in this direction. The switching trials we could find go the other way — for example SURPASS-SWITCH and SURPASS-SWITCH-2, which moved people with type 2 diabetes from other GLP-1 medications onto tirzepatide. We found no trial that moved people from tirzepatide to semaglutide.
• Clinical guidance says the same thing. The Pharmaceutical Journal review states there is "no validated dose equivalence" between the two agents, owing to their differing receptor profiles, and notes that no NICE or MHRA guidance (the UK's clinical-guideline body and its medicines regulator) specifies how to make the switch.

The reason is pharmacological. Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GLP-1 and GIP receptors. "10 mg of tirzepatide" and "some number of mg of semaglutide" are not two points on the same scale.

You will find conversion tables online — on telehealth blogs and dose-calculator sites — that map each tirzepatide dose to a semaglutide dose. The ones we looked at do not cite a label or a switching trial. We are not reproducing them here, because a tidy table would imply a precision that the evidence does not have.

What dose of semaglutide do you start on?

What the label says: the recommended starting dosage of Wegovy injection is 0.25 mg once weekly, followed by step-ups every 4 weeks. The label lists no exception for people who were previously on tirzepatide. (Its only switching instructions cover moving between Wegovy injection and Wegovy tablets.)

What informal clinical guidance says: The Pharmaceutical Journal review calls restarting at the lowest semaglutide dose, then titrating on the standard schedule, the "safest approach" — "regardless of the previous tirzepatide dose." Be clear about what kind of source that is: a UK expert review that describes itself as extrapolating from general GLP-1 switching principles, not a trial result.

Here is how the two weight-management labels compare. This is a side-by-side of what each label says — not a conversion table:

	Tirzepatide (Zepbound)	Semaglutide (Wegovy injection)
Receptors activated	GLP-1 and GIP	GLP-1 only
Starting dose	2.5 mg weekly	0.25 mg weekly
Step-up schedule	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg, at least 4 weeks per step	0.25 → 0.5 → 1 → 1.7 → 2.4 mg, 4 weeks per step
Maintenance doses (weight reduction)	5, 10, or 15 mg	1.7 or 2.4 mg; up to 7.2 mg for adults after at least 4 weeks tolerating 2.4 mg
Other labeled uses	Obstructive sleep apnea	Cardiovascular risk reduction; MASH
Tablet form	No	Yes
Label guidance on switching from the other drug	None	None

If you are moving to Ozempic rather than Wegovy (same molecule, diabetes label), the schedule and the ceiling are different — Ozempic tops out at 2 mg weekly. Our Ozempic titration guide walks through each step.

Some prescribers may decide an experienced patient doesn't need to begin at the very bottom. That is an individual clinical judgment made off-label-schedule, and no published evidence tells us how it compares with a full restart. Your prescriber sets the dose; this article can't.

How long should you wait between your last tirzepatide dose and your first semaglutide dose?

The labels don't specify a gap. What they do say, in both directions, is that using the two drug types together is not recommended: the Wegovy label says concomitant use with any other GLP-1 receptor agonist is not recommended, and the Zepbound label says the same about coadministration with any GLP-1 receptor agonist.

The pharmacology behind the question: the Zepbound label gives tirzepatide's elimination half-life as approximately 5–6 days. By the standard rule of thumb that a drug is mostly gone after about five half-lives, tirzepatide is still in your system for roughly a month after your last injection — so some overlap is unavoidable unless you wait that long, and waiting that long means a stretch with falling medication levels.

The Pharmaceutical Journal review describes two approaches clinicians use:

• A one-to-two-week washout before starting semaglutide, which it describes as preferred for people who had significant side effects on tirzepatide.
• A same-day switch — starting semaglutide on the day your next tirzepatide dose would have been due — for people who were stable and tolerating treatment, where the clinician judges the risk of heightened side effects to be low.

No study has compared these two approaches for this switch. Which one fits you is a prescriber decision, based on why you are switching and how you tolerated tirzepatide.

Will you lose less weight on semaglutide?

This is the question the reverse-direction articles don't have to answer, and it deserves a straight one.

The head-to-head trial favored tirzepatide. SURMOUNT-5 randomized 751 adults with obesity (without type 2 diabetes) to maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks:

	Tirzepatide	Semaglutide
Mean weight change at week 72	−20.2%	−13.7%
Waist circumference change	−18.4 cm	−13.0 cm

The difference was statistically significant (p<0.001). The trial was funded by Eli Lilly, tirzepatide's manufacturer.

Three things that trial does not tell you:

1. It did not study switching. Everyone started their assigned drug from scratch. What happens to weight when someone who has already lost weight on tirzepatide moves to semaglutide has not been studied. Regain, holding steady, and continued loss are all possible, and nobody has measured how often each occurs.
2. It capped semaglutide at 2.4 mg. The current Wegovy label allows an increase to a maximum of 7.2 mg weekly for weight reduction in adults who have tolerated 2.4 mg for at least 4 weeks. SURMOUNT-5 did not test that dose, so there is no head-to-head result for tirzepatide against semaglutide 7.2 mg.
3. It reports averages. Individual responses to both drugs vary widely.

One modelling study suggests where you might land after re-titrating — not where you start. A 2026 analysis in Diabetes Therapy (Builes-Montaño and colleagues) pooled results from 48 treatment arms of phase 3 trials (16,524 participants) and modelled the dose-response curves of both drugs. It estimated a high probability that these dose pairs produce equivalent average weight loss, within 2 percentage points:

• Semaglutide 2.4 mg and tirzepatide 10 mg (99.4% probability of equivalence)
• Semaglutide 7.2 mg and tirzepatide 15 mg (94.8% probability of equivalence)

Read those numbers with their caveats attached, because the caveats are large:

• The population is people with type 2 diabetes. Every trial in the model was a type 2 diabetes trial. Whether the same dose pairs hold for people who take a GLP-1 for weight management without diabetes was not tested.
• It is a statistical model, not a trial. It compared group averages across separate studies. The authors themselves list this as a limitation: with no individual patient data, they could not adjust for differences between the trial populations.
• It was funded by Novo Nordisk, semaglutide's manufacturer, and two of its three authors are Novo Nordisk employees.
• It modelled weight loss only — not side effects, tolerability, or what happens during a switch. The authors write that equivalence "should not be interpreted as therapeutic interchangeability in all contexts."
• It is not a conversion chart. It describes the average result of people who were titrated up to a dose and held there. It says nothing about what dose to begin semaglutide on after tirzepatide.

The fair summary: if you were on 10 mg of tirzepatide, a modelling study in a different population suggests semaglutide 2.4 mg may eventually produce a similar average effect — after months of re-titration. That is a hypothesis about a destination, and it has not been tested in people who actually made the switch.

What should you expect in the first few weeks?

There is no study of what the first weeks of this specific switch feel like, so what follows is reasoned from each drug's label and titration design rather than from switch data.

• Appetite control may feel weaker for a while. If you start at 0.25 mg, you are on a dose the titration schedule uses to build tolerance, while your tirzepatide level is falling. A period where hunger feels less controlled is a plausible consequence of that pharmacology — not a sign the new medication is failing.
• GI side effects can return. In SURMOUNT-5, gastrointestinal events were the most common adverse events on both drugs and occurred mainly during dose escalation. Re-titrating means going through escalation again. The Wegovy label says that if a dose isn't tolerated during escalation, delaying the next step-up by 4 weeks can be considered.
• Reaching a full dose takes months. On the standard Wegovy schedule, 2.4 mg begins at week 17. Any move to 7.2 mg comes after at least 4 more weeks at 2.4 mg, and only if your prescriber judges further weight reduction is clinically indicated.
• The scale may be noisy. Watch the multi-week trend rather than any single weigh-in, and don't judge the switch until you have been at a maintenance dose long enough to see one.

The fundamentals don't change with the molecule: keep your protein target, keep meals structured through any nausea windows, and keep resistance activity going — a period of weaker appetite control is when those habits do the most work. For how the side-effect profiles compare stage by stage, see Ozempic vs Wegovy vs Mounjaro: side effects compared.

Setting up the switch in GLP-1 Coach

The app tracks semaglutide and tirzepatide as separate molecules — half-life, dose-warning thresholds, and titration steps are keyed to each medication — so the switch doesn't need a workaround:

1. Go to Settings → Medication and change your medication to Wegovy · Ozempic (semaglutide). Your logged history isn't deleted — past entries stay attached to tirzepatide.
2. Your week count restarts from today for the new medication, so the app frames your titration stage and nausea-pattern insights as week 1 of semaglutide, not a continuation of your tirzepatide weeks.
3. Update your pen selection to the dose your prescriber actually started you on (for example Wegovy — 0.25 mg), so dose logging and the medication-level chart reflect the real molecule and dose rather than a leftover tirzepatide value.
4. Start a new projection in the taper planner if you use it — one built on your tirzepatide data won't reflect semaglutide's longer half-life or your new dose schedule.

The bottom line

Bottom line: There is no FDA-approved or validated dose conversion from tirzepatide to semaglutide, no label instruction for this switch, and no study that followed people through it. What is documented: the Wegovy label starts at 0.25 mg weekly with no exception for prior tirzepatide use, both labels advise against using the two drug types together, and a 2026 clinical review describes restarting low — after either a one-to-two-week washout or a same-day switch — as the cautious default. In the one head-to-head trial, semaglutide at up to 2.4 mg produced less average weight loss than tirzepatide (13.7% vs. 20.2%); whether the newer 7.2 mg dose closes that gap rests on a manufacturer-funded modelling study in people with type 2 diabetes, not on a trial. Starting dose, timing, and target dose are your prescriber's decisions.

Final Thoughts

Most people making this switch didn't choose it for clinical reasons — a formulary changed, a side effect didn't settle, or a prescriber wanted a drug with a specific labeled use. That context matters for how you judge it. A few rough weeks at a low semaglutide dose is the expected shape of re-titration, not evidence that the switch has failed, and the comparison that counts is how you are doing at a stable maintenance dose several months in.

It is also worth being honest about what nobody knows yet. Switching from tirzepatide to semaglutide rose sharply after mid-2025, and we could find no published outcome data on how those patients did. Until there is, anyone offering a confident mg-for-mg conversion is offering more certainty than the evidence contains. The useful questions to bring to your prescriber are concrete: what dose am I starting on and why, how long should I wait after my last tirzepatide dose, what is the target dose, and — if coverage was the reason — is this switch still necessary under my plan today?

---

Related:

• Switching from Semaglutide to Tirzepatide: Ozempic/Wegovy to Zepbound/Mounjaro
• Insurance Dropped Your GLP-1? What to Do Next
• Ozempic Titration: What Changes at Each Dose
• Stopping Mounjaro or Zepbound: What to Expect

---

This article is educational and not a substitute for medical advice. The decision to switch medications, the starting dose, the timing between your last tirzepatide dose and your first semaglutide dose, and any later dose increase should be made with the prescriber managing your care — not inferred from this article.

Sources: WEGOVY full prescribing information, DailyMed/FDA (revised 6/2026); ZEPBOUND full prescribing information, DailyMed/FDA (revised 8/2026); Aronne LJ, Horn DB, le Roux CW, et al., "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity," SURMOUNT-5, New England Journal of Medicine 2025;393:26-36; SURMOUNT-5 journal scan, American College of Cardiology; Shahid S, "Switching between weight-loss medications," The Pharmaceutical Journal, July 2026; Builes-Montaño CE, Suarez-Rodriguez AF, Alzate-Vinasco MA, "Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis," Diabetes Therapy 2026;17(7):1067-1083; Truveta Research, "Impact of the CVS GLP-1 formulary change: Trends in switching," September 2025 (preliminary, not peer reviewed); CVS Caremark GLP-1 coverage announcement, CVS Health, May 28, 2026; SURPASS-SWITCH trial protocol, ClinicalTrials.gov NCT05564039; SURPASS-SWITCH-2 trial protocol, ClinicalTrials.gov NCT05706506.